Using Nanoparticles to Reduce Drug Toxicity in Pancreatic Cancer Patients - ACS Axial
Search
Close

Using Nanoparticles to Reduce Drug Toxicity in Pancreatic Cancer Patients

Sometimes the treatment for a disease can be almost as dangerous as the ailment it seeks to cure. In the case of pancreatic cancer, one of the most effective drug regimens, FOLFIRINOX, contains a highly toxic drug called irinotecan. Huan Meng and Xiangsheng Liu are authors on a recent paper in ACS Nano on a way to use nanoparticles to help reduce the toxicity of the regimen. Their research describes the custom-designing of a mesoporous silica nanoparticle platform to deliver irinotecan directly to cancerous cells, instead of releasing it into the rest of the body.

Watch them describe their research:

Want to learn more? Read their research in ACS Nano.

Add a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Want more stories like this delivered to your inbox?

Sign up for our newsletter to receive a selection of stories related to your favorite topics.